Psyence Biomedical Ltd. (NASDAQ:PBM) traded at $0.10 at close of the session on current trade day and made an upward move of 1.35% on its previous day’s price.
Looking at the stock we see that its previous close was $0.10 and the beta (5Y monthly) reads -0.477 with the day’s price range being $0.0921 – $0.104. In terms of its 52-week price range, PBM has a high of $14.55 and a low of $0.08. The company’s stock has lost about -37.31% over that past 30 days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Psyence Biomedical Ltd. has a market cap of $1.63 million and is expected to release its quarterly earnings report in November.
Looking further, we note the current price level is -10.15% off its SMA20 and -65.25% from its 50-day simple moving average. The RSI (14) is pointing at 28.42 while the volatility over the past week is 14.30% and jumps to 14.56% over the past one month. The beta value is -0.48, while the average true range (ATR) is currently pointing at 0.02.
Coming back to Psyence Biomedical Ltd. (NASDAQ:PBM), we note that the average 3-month trading volume was 5.24 million, while that of the preceding 10-day period stands at 7.28 million. Current shares outstanding are 13.39 million.
The insiders hold 44.17% of the company’s shares while institutions hold 5.43%. The data shows that short shares as of 2024-09-30, stood at 0.22 million at a short ratio of 0.03. This represents a 61.00 short interest in shares outstanding on 2024-09-30. Shares short fall in September from the previous month at 0.29 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -98.94% down in year-to-date price movement.
